DCM
ORIC icon

DAFNA Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

DAFNA Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-98,724
Closed -$945K – 95
2026
Q1 		$945K Sell
98,724
-42,321
-30% -$480K 0.22% 62
2025
Q4 		$1.15M Buy
141,045
+36,374
+35% +$419K 0.27% 59
2025
Q3 		$1.26M Sell
104,671
-30,600
-23% -$322K 0.31% 57
2025
Q2 		$1.37M Sell
135,271
-106,729
-44% -$717K 0.38% 48
2025
Q1 		$1.35M Buy
+242,000
New +$2.12M 0.38% 46
2024
Q3 		– Sell
-36,000
Closed -$255K – 85
2024
Q2 		$255K Buy
+36,000
New +$322K 0.06% 77
2024
Q1 		– Sell
-72,797
Closed -$670K – 79
2023
Q4 		$670K Buy
+72,797
New +$526K 0.16% 62
2023
Q2 		– Sell
-170,326
Closed -$971K – 77
2023
Q1 		$971K Sell
170,326
-93,911
-36% -$491K 0.29% 46
2022
Q4 		$1.56M Sell
264,237
-149,289
-36% -$504K 0.44% 50
2022
Q3 		$1.32M Sell
413,526
-2,400
-0.6% -$9.61K 0.36% 51
2022
Q2 		$1.86M Buy
+415,926
New +$1.66M 0.51% 48

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DAFNA Capital Management's ORIC Position: Q2 2026 in Review

DAFNA Capital Management sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 98,724 shares — an estimated $945K sold.

DAFNA Capital Management first reported a position in ORIC in Q2 2022 and held it in 11 quarters. The position peaked at $1.86M in Q2 2022. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • DAFNA Capital Management reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • DAFNA Capital Management sold 98,724 Oric Pharmaceuticals shares in Q2 2026, an estimated $945K.
  • DAFNA Capital Management first reported a position in Oric Pharmaceuticals in Q2 2022 and held it in 11 quarters.
  • DAFNA Capital Management's Oric Pharmaceuticals position peaked at $1.86M in Q2 2022.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.